Alexandria Forbes, Ph.D.President and CEO
Dr. Alexandria Forbes has served as our President, Chief Executive Officer and a member of our board of directors since March 2015. Prior to joining MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015 and currently serves as a member of its board of directors. Prior to Kadmon Holdings, Inc., Dr. Forbes spent eleven years as a healthcare investor at Sivik Global Healthcare, a healthcare hedge fund, from September 2000 to November 2008, and at Meadowvale Asset Management, a healthcare hedge fund, from January 2010 to June 2012. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center from March 1997 to September 2000. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University. Dr. Forbes received an M.A. in Natural Sciences from Cambridge University and a Ph.D. in Molecular Genetics from Oxford University.
Stuart Naylor, Ph.D.Chief Development Officer
Dr. Stuart Naylor has served as our Chief Development Officer and a member of our board of directors since April 2015. From April 2015 to April 2016, Dr. Naylor was Chief Executive Officer of Athena Vision, a biotechnology company. From June 2013 to April 2015, Dr. Naylor served as managing director of Coltivare Ltd., a healthcare consulting company. From 2008 to 2013, Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, a gene therapy company. Prior to joining Oxford BioMedica, Dr. Naylor focused on translational cancer research at the Institute of Cancer Research. Dr. Naylor has a B.S.C. in microbiology and virology from the University of Warwick, a M.S. in Immunology from Kings College London, and a Ph.D. from the Imperial Cancer Research Fund laboratory studying ovarian cancer and cytokine biology.
Richard GirouxChief Operating Officer
Richard Giroux has served as our Chief Operating Officer since March 2015. Mr. Giroux joined MeiraGTx from Sarissa Capital Management LP, an activist healthcare hedge fund, where he was a partner from March 2014 to March 2015. Prior to Sarissa Capital, Mr. Giroux was a founding partner and healthcare portfolio manager of Meadowvale Partners, a multi-strategy hedge fund, from January 2010 until June 2012. Mr. Giroux received a B.A. in Economics from Yale University.
Gregory A. Petsko, Ph.D.Chief Scientist
Dr. Gregory A. Petsko is the Chief Scientist at MeiraGTx. He is the Arthur J. Mahon Professor of Neurology and Neuroscience at Weill Cornell Medical College in New York City, and Director of the Helen and Robert Appel Alzheimer’s Disease Research Institute. He also holds appointments as Adjunct Professor of Biomedical Engineering at Cornell University, Adjunct Professor of Neurology at Harvard Medical School, and Tauber Professor of Biochemistry and Chemistry, Emeritus, at Brandeis University. He has been elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society. He is the co-founder of several publicly-traded biotechnology companies and is one of the founding editors of the PLoS family of journals. His research interests include protein structure and function and the development of methods to treat age-related neurodegenerative diseases, including ALS (Lou Gehrig’s), Alzheimer’s and Parkinson’s diseases.
Robin Ali, Ph.D.Head of Preclinical Ophthalmology
Professor Robin Ali is Head of Preclinical Ophthalmology of MeiraGTx. He is also Professor of Human Molecular Genetics at UCL Institute of Ophthalmology. Additionally, he is the Theme Leader for Gene Therapy at NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and a Visiting Professor at The Kellogg Eye Center, University of Michigan. Prof. Ali established the world’s first clinical trial of gene therapy for retinopathy. In 2007, he was elected to the UK Academy of Medical Sciences and in 2009 appointed Senior Investigator of The UK National Institute of Health Research. He is the President of the European Society of Gene and Cell Therapy and has served on the advisory boards of a number of funding bodies including the UK Medical Research Council (Neurosciences and Mental Health Board and the Regenerative Medicine Research Committee), Research to Prevent Blindness USA and Fighting Blindness Ireland, as well as the advisory boards of pharmaceutical and biotech companies, including Alcon/Novartis. Prof. Ali obtained his BSc (1988) and PhD in Genetics (1993) at University College London, carried out his postdoctoral training at the MRC National Institute for Medical Research and the UCL Institute of Ophthalmology and established his laboratory at the UCL Institute of Ophthalmology in 1999.
Christine SheehySVP Global Integration
Christine Sheehy is SVP Global Integration of MeiraGTx. Ms. Sheehy is a pharmaceutical business leader with over 25 years of experience in designing and executing operational, financial and organizational infrastructure. Most recently, Ms. Sheehy was SVP of Operations for Kadmon Pharmaceuticals leading the global supply chain, distribution, and IT organizations. Ms. Sheehy was a founding member of start-up pharmaceutical company, Three Rivers Pharmaceuticals, acquired by Kadmon in 2010. During that time, she launched branded and generic products in the U.S. leading the operational business. Globally, she executed international supply and distribution partnerships in Europe and Asia. Prior to Three Rivers Pharmaceuticals, Ms. Sheehy was in a business consulting/finance role for Schneider Downs, specializing in finance and technology in various industries. She also held various finance management roles for Ametek, Inc. Ms. Sheehy was on the board of directors of GPhA from 2006-2008 and also served on various Oracle organizations, Oracle Leaders’ circle- 2010 and 2014, Oracle Women’s Leadership (OWL) program – 2014 and the Oracle Customer Advisory Board.
Lisa Speicher, Ph.D.U.S. Clinical Operations
Dr. Lisa Speicher leads U.S. Clinical Operations for MeiraGTx. She brings 25 years of clinical and translational research experience obtained in academia and biotechnology/pharmaceutical companies. She has a broad spectrum of therapeutic area experience in adults and children with specialization in oncology and gene therapy. Her experience prior to MeiraGTx includes: Executive Director of Clinical Research at the University of Pennsylvania’s Perelman School of Medicine; Director of the Clinical Trials Office and the Office of IND/IDE support at the Children’s Hospital of Philadelphia (CHOP); and Director of the Oncology Program for the Department of Experimental Medicine at Wyeth. She earned her Ph.D. in Physiology at Thomas Jefferson University and conducted post-doctoral research specialized in cancer drug resistance at the Fox Chase Cancer Center in Philadelphia, PA.
Micah ZajicVP Corporate Development
Micah Zajic is Vice President of Corporate Development for MeiraGTx. Mr. Zajic joined MeiraGTx from Alexion Pharmaceuticals, where he worked in Corporate Strategy and Business Development, primarily focused on the evaluation and execution of external partnerships, license agreements and acquisitions. Prior to joining Alexion, Mr. Zajic spent 10 years at Morgan Stanley in a variety of positions within Healthcare Investment Banking, Global Capital Markets and the Investment Management Division. During this time, he executed several strategic transactions and financings for clients across all healthcare subsectors. Mr. Zajic received his BA in Economics from Georgetown University in 2003.